By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...